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Abstract There are approximately 23 million patients with
heart failure (HF) worldwide. The prognosis of patients
with HF is still poor and a prospective approach for
preventing and treating HF is necessary. The number of HF
patients in Japan has been increasing since 1950 mainly
because of a rapidly aging population. Furthermore,
westernized dietary pattern, reduced physical activity, and
obesity have become prominent, particularly in younger
Japanese men. There is an increasing trend of diabetes and
dyslipidemia, and the prevalence of smoking and hyperten-
sion continues to remain high. One of the largest HF
cohorts in Japan, the CHART Studies, showed that
coronary artery disease (CAD) was the most frequent
etiology of HF currently. Thus, prospective strategies
including accurate risk stratification, effective prevention
of disease progression through evidence-based treatments,
optimally personalized treatment particularly in elderly
individuals, and life-long control of CAD risk factors are
required to manage HF in Japan.
Keywords Prevention . Personalized medicine . Coronary
artery disease . Cardiovascular risks . Elderly .
Undertreatment
Worldwide increase in the number of patients with heart
failure: importance of a prospective approach
Chronic diseases such as heart disease, stroke, cancer, chronic
respiratory diseases, and diabetes mellitus (DM) are the
leading causes of morbidity and mortality worldwide [1].
Patients with such diseases account for approximately two-
thirds of all healthcare expenses. Typical medical interven-
tion for patients with chronic diseases usually occurs during
the latter stages of disease progression and the long-term
prognosis remains poor despite the high costs of care.
Healthcare systems in the developed countries are now
changing their orientation from a disease-based approach to a
prospective approach thereby focusing on predictive, pre-
ventive, and personalized medicine [2]. A key feature of
such new approaches is strategic and personalized health
planning. This includes new abilities to detect disease at an
earlier stage, identify individuals at a higher risk of certain
diseases, prevent disease progression, reduce healthcare
costs, and ensure optimal treatment for each patient.
Heart failure (HF) is a complex syndrome that can result
from structural or functional cardiac disorders. There has
been an increase in the number of HF patients in the
developed and developing countries. There are approxi-
mately 23 million patients with HF worldwide and 2
million patients are newly diagnosed with HF every year
[3]. In the USA, the prevalence of HF in 2007 was 5.7
million and approximately 1 in 9 death certificates
mentioned HF as the cause of death [4]. Furthermore, there
were 670,000 new cases each year, with approximately 1
million hospitalizations due to worsening HF. The estimated
healthcare cost of HF in 2010 was US $39.2 billion [3, 4].
Although the epidemiology of HF in most developing
countries is poorly established, an increase in the impor-
tance of cardiovascular diseases (CVD) as well as coronary
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artery disease (CAD), in such countries may lead to an
increased incidence and prevalence of HF in the future [5].
Otherwise, the mortality rates due to CVD have been
declining in North America, Europe, Australia, and New
Zealand since decades. However, mortality rates have been
increasing in the former Eastern Bloc countries, Latin and
South America, India, China, and Africa [5]. The reasons
for the increasing trend of HF worldwide are: (i) advance-
ment in the control of infectious, parasitic, and nutritional
diseases in developing countries, which has led to CVDs
being increasingly recognized (ii) more people can reach
the age at which CVDs manifest (especially in developed
countries) (iii) HF usually develops at the final stage in the
long-standing process of CVD.
The prevalence of CVD in Japan remains low. The age-
adjusted mortality (standardized mortality rate in the Japanese
population in 1985) from heart diseases has been declining
recently. However, Japan has the most advanced aging society
in the world and the crude number of patients who die as a
result of heart diseases (of which the major part was considered
to be HF) has been increasing dramatically for decades [6, 7].
We have been conducting a multicenter prospective cohort
study of HF patients named the Chronic Heart Failure
Analysis and Registry in the Tohoku District (CHART-1; N=
1278) since 2000. We reported that the mortality rate of HF
patients in Japan was high and was comparable with that seen
in the Western countries [8, 9].
Guidelines for the diagnosis and management of HF in
adults set by the American College of Cardiology (ACC)
Foundation / American Heart Association (AHA) have
proposed a new classification of HF consisting of stages A,
B, C, and D to emphasize the development and progression
of HF [10]. Stage-A and -B patients are defined as those
with risk factors that clearly dispose toward the develop-
ment of HF. Stage C denotes patients with current or past
symptoms of HF. Stage D denotes patients with truly
refractory HF (Fig. 1). This classification shows that there
are established risk factors and structural prerequisites for
the development of HF. It also shows that the therapeutic
interventions introduced even before the manifestation of
structural disorders or symptoms can improve the prognosis
of HF. Other authoritative HF guidelines published by
organizations in several other developed countries have also
underscored the importance of thorough care of patients at
high risk of developing HF in addition to appropriate
treatment for those with overt HF [10–13].
We started a new cohort named the CHART-2 Study in
2006 which included patients at high risk of developing HF
as well as those with overt HF, and recently closed the entry
period of the study [14]. This review summarizes the recent
trends involved in development or exacerbation of HF in
Japan as well as the clinical characteristics of Japanese
patients with HF. Furthermore, we underscore the impor-
tance of a prospective approach in treating patients with
CVD or those with a risk of developing HF in order to
improve the prognosis of such patients.
The declining birthrate and aging population in Japan
The population of Japan surpassed 100 million in 1967 but
the population growth has recently slowed. The annual
growth of the population from 1960 to 1980 was
approximately 1%. However, the population of Japan began
to decrease since 2005, and the total population in 2009
was 127.51 million [7]. The age structure diagram of 1950
shows that Japan had a standard-shaped pyramid charac-
terized by a broad base. However, it represents a constric-
tive pyramid in 2009, which indicates lower percentage of
younger population and longer life expectancy (Fig. 2). In
2009, the population of individuals aged ≥65 years was
29.01 million, constituting 22.7% of the total population. In
Japan, the rate of aging has been high since the 1970s
compared with that in other Western or Asian countries; the
percentage of elderly population (≥65 years) is estimated to
reach 39.6% by 2050 (Fig. 3) [15]. The mean life
expectancy at birth in Japanese individuals continued to
improve after World War II; it was 79.6 years for men and
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86.4 years for women in 2009 [7]. The percentage of
younger age population (0–14 years) has been decreasing
since 1982, which was 13.3% of the total population in
2009 [7]. The major reason for this declining trend is the
recent low birth rate seen in the Japanese population, which
was more prominent since the late 1970s. The birth rate in
2009 was as low as 8.5 per 1,000 population [7].
This trend showing a rapid increase in the elderly
population will further increase the number of patients with
CVD or HF. These patients would need a more personalized
strategy in evaluation and treatment of disease compared
with middle-aged patients (see below).
“Lifestyle Westernization” among Japanese people
Multiple dietary factors are strongly associated with athero-
sclerotic disease (including CAD) and appropriate diet
modification can have beneficial effects. A common feature
of the diets that help to prevent CAD is the emphasis on plant-
based foods. These foods are characterized by a high intake of
fiber and a low intake of saturated fat. Furthermore, in Japan,
if the total fat intake is >30% kcal, the predominant fat is
monounsaturated fats [16]. Although the impact of these
dietary patterns in the primary prevention of atherosclerotic
disease is important, there are a few clinical trials that
directly compare the effect of different diets on CVD risk.
The dietary pattern in Japanese individuals has changed
with a higher intake of animal fat and protein, and a lower
intake of carbohydrates [17]. The National Nutrition Survey
of Japan (NNSJ) reported that the intake of dietary fat as a
percentage of energy was approximately 8% in 1950, which
has rapidly increased by 3.8-fold over the past 50 years
[18]. In men and women, the mean total intake of calories
in 2009 was 2073 kcal and 1677 kcal, respectively, whereas
percentage intake of energy as fat was 25.1% and 26.7%,
respectively. It is important to note that individuals aged
20–29 years who were consuming ≥30% of total energy in
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Studies have shown an inverse association between
physical activity and the risk of developing CVDs such as
CAD and stroke in men and women [19]. Meta-analyses of
prospective observational studies revealed that moderately
active men experienced 20-30% less age-adjusted rates of
CAD and all-cause mortality compared with the least active
men [20]. Regular physical activity of an adequate amount
and intensity prevents the development of atherosclerosis
and improves several cardiovascular risks which are
causally linked to the progression of atherosclerosis (e.g.,
obesity, hypertension, dyslipidemia, diabetes, and smoking).
Shibata et al. evaluated the relationship between physical
activity and death fromCVD using prospective data involving
12490 Japanese participants. They reported that more physical
activity was associated with a reduced risk of death from
CVDs [21]. The NNSJ showed an overall increase in the
number of individuals who had regular exercise habits since
1987 (Fig. 4) [18]. However, a stable or decreasing trend of
physical activity was prominent in men and women aged
20–39 years.
An increased intake of animal fat and relatively less
physical activity in the younger Japanese population may
have an impact on the development of CVD or HF. These
findings warrant long-term monitoring of lifestyle and
cardiovascular risks in those individuals.
Trends in risks of CVD and HF in Japan
Hypertension or raised blood pressure (BP) carries a
definite risk of developing CVD. Successive lowering of
BP will lead to cumulative reduction in the risk of
developing CVD. Ueshima et al. reported the long-term
trend of BP in a Japanese population using the NNSJ
(which has been conducted since World War II) [6]. They
reported that systolic blood pressure (SBP) showed a decline
since 1965 in men aged ≥50 years and in women of all age
groups; the reduction in SBP for individuals aged ≥60 years
almost reached ≥15 mmHg during 1965–2000. The
prevalence of individuals with hypertension has also
decreased since 1980 in all age groups (Fig. 5) [18].
There is clear evidence that increased consumption of salt
is a major factor in increasing BP [22] and that the major
reason for individuals showing decreasing trend for
hypertension in Japan is due to reduced intake of salt.
Salt consumption in northern Japan was 26–27 g/day in
the 1950s; it decreased significantly to 13 g/day in 2001
and 11 g/day in 2008 [18].
However, Martiniuk et al. reported that the crude
prevalence of hypertension in Japan in 2000 was 41.4%
and 31.9% in men and women, respectively, and that the
prevalence was the second highest in the WHO-defined
Western Pacific and South-east Asian regions [23]. They
reported that the sex-specific population-attributable frac-
tion of fatal CAD attributable to hypertension was
approximately 15% in men and 39% in women. The report
of the Asia Pacific Cohort Studies Collaboration (APCSC)
showed continuous log–linear associations between SBP
and incidence of CAD [24]. A 10-mmHg decrease in SBP
was associated with 46%, 24%, and 16% lower CAD risk
in individuals aged <60, 60–69, and ≥70 years, respectively.
Further reductions in the prevalence of hypertensive
individuals should be given high priority in many countries
(including Japan) to prevent the development of
hypertension-related CVD, which is a major cause of HF.
Individuals with DM are also at an increased risk of
death from various types of CVDs. The APCSC analyzed
24 population-based cohort studies from Asia, Australia,
and New Zealand [25]. This study included 29089 Japanese
individuals (aged 20–96 years) and the mean prevalence of
DM at study entry was 3.3%. During a median follow-up of
5.4 years, they showed that age-, sex-, and study-adjusted
hazard ratios (HRs) for fatal CAD associated with DM were
2.22 in the Asian population. In addition, there was no
significant change in the HR after multivariable adjustment
including BP, cholesterol, body mass index (BMI), and
smoking status. It is important to note that the relative effect
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Fig. 4 Trend of regular exercise habit in Japanese individuals [18]
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was almost identical to that in Caucasian populations. The
prevalence of DM has been increasing more rapidly
throughout Asia compared with that in the Western
countries. Wild et al. reported that individuals with DM in
Japan would increase from 6.8 million in 2000 to 8.9 million
in 2030 [26]. The NNSJ showed that the prevalence of
individuals diagnosed as having DM or whose hemoglobin
A1c level was ≥6.1% was 8.2%, 9.0%, and 10.5% in the
years 1997, 2002, and 2007, respectively [27]. This survey
also revealed that the increase in prevalence was more
prominent in individuals aged ≥60 years and that 22.1
million Japanese people were considered to have DM (or the
possibility of having glucose intolerance) in 2007 (Fig. 6).
Asian populations are less obese compared with Western
populations. The BMI in Asians is approximately 20–24 kg/m2,
whereas it is 26–29 kg/m2 in the Westerners [28]. However,
age-adjusted BMI has increased since 1956 in the Japanese
population [29]. The NNSJ revealed that the prevalence of
Japanese male individuals with BMI ≥25 kg/m2 has been
increasing (Fig. 7) and the mean prevalence was 16.8%,
25.8%, and 30.5% in the years 1979, 1999, and 2009,
respectively [18]. The BMI of Japanese women has been
relatively stable for the last 30 years (Fig. 7) and the mean
prevalence of Japanese females with a BMI ≥25 kg/m2 was
approximately 20% [18]. Increased BMI is also associated
with raised BP, glucose intolerance, dyslipidemia, and
development of CVD in Japanese population. The analysis
of NIPPON DATA showed that there was a significant dose–
response relationship between the BMI and odds ratio for
hypertension in men and women [30]. This analysis also
revealed that the percentage of individuals with hypertension
attributable to obesity in 1980 and 1990 was 11.4% and
15.3% for men and 19.3% and 22.3% for women,
respectively. Furthermore, Shiraishi et al. reported that a
BMI ≥25 kg/m2 was significantly associated with the
development of acute myocardial infarction (AMI) in young
and middle-aged Japanese men [31]. These findings suggest
that obesity is now playing an important role in the
development of cardiovascular risks and CVD in Japan.
Cigarette smoking has been associated with atheroscle-
rotic disease (including CAD and stroke) throughout the
world. The report of the APCSC in 2005 stated that 51–
76% of men and 1–17% of women in Japan were current
smokers from 1974 to1997 [32]. This study revealed that
the HR of current smokers for CAD was 1.60 compared
with non-smokers in Asia, Australia, and New Zealand;
there was a clear dose–response relationship between the
number of cigarettes smoked per day and the incidence of
CAD. The prevalence of smoking in Japanese men declined
from 46.8% in 2003 to 38.2% in 2009, whereas that in
Japanese women is relatively lower compared with that in
men, but remains high (11.3% in 2003 and 10.9% in 2009)
[18, 28]. Martiniuk et al. reported that the fraction of CAD
attributable to smoking in Japanese men and women in year
2000 was 22% and 7%, respectively [33]. Smoking control
must be more emphasized to reduce the prevalence of CVD
















































































Fig. 6 Recent trend of percentage of individuals with DM by age







































































Fig. 5 Trend of percentage of individuals with hypertension by age [18]
EPMA Journal (2011) 2:425–438 429
Dyslipidemia is a well-established risk factor for CAD.
Serum levels of total cholesterol (TC) in individuals of
Asian countries (except Singapore) are generally far lower
than those in the USA and other Western countries [28]. It
was <190 mg/dL in 1980 in all age groups, and has
significantly increased in recent years (>200 mg/dL in
middle-aged men) (Fig. 8). However, the serum level of TC
in the elderly Japanese population is lower than that of
Western populations [34]. Although Japanese women aged
50–69 years showed a relatively high serum TC level
(Fig. 8), the impact of raised TC or low-density lipoprotein
cholesterol (LDL-C) between men and women might be
different. Noda et al. after evaluating 91219 Japanese
individuals without stroke and CAD, reported that a higher
LDL-C level was associated with an increased risk of
mortality from CAD in men but not in women [35]. Arai et
al. evaluated the 40-year trend of lipid profiles in 12839
Japanese individuals [36]; they reported that the increase in
TC level was attributed to an increase in the level of high-
density lipoprotein cholesterol, and not LDL-C. The
triglyceride level in Japanese population increased over
the last 10 years, which was mainly attributed to the
increase of that in middle-aged men; the authors anticipate
a further increase in the incidence of hypertriglyceridemia
in the future. In Japan, high consumption of fish and rice
have contributed in keeping the serum level of TC lower
than that of Western countries [34, 37]. Recently, the intake
of animal protein and fat in the Japanese population has
increased significantly [38]. The impact of such alterations
in dietary habits on the lipid profile should be evaluated.
Trends in mortality and incidence of CAD in Japan
Japan has the lowest mortality rate from CAD among the
industrialized countries [19]. Mortality from CAD began to
decline by 1970 in most countries. Age-adjusted mortality
due to all heart diseases and CAD in Japan increased until
1970 and then continued to decrease gradually (Fig. 9) [7].
However, the crude mortality rate from all heart diseases,
CAD other than AMI and HF has been increasing since the
1970s; crude mortality from AMI has decreased gradually
since 1995 (Fig. 9). The major reason for such trends
includes the rapidly aging Japanese society. The incidence
rate of AMI was much lower than that in other industrial-
ized countries [34]. Several reports from the USA showed a
substantial decrease in CAD incidence beginning in 1970
[39, 40]. However, it remains controversial whether the
incidence rate of AMI in Japan has decreased or not.
Kodama et al. evaluated the incidence of CAD from a 26-year
follow-up study, which included 19961 subjects and reported
that the age-adjusted incidence of AMI remained almost
constant from 1958 to 1984, averaging 2.1/1000 person-years
in men and 0.79/1000 person-years in women [41]. Kitamura
et al. reported an increasing trend of age-adjusted CAD
incidence in Japanese men since 1980 in the rural and urban
areas [42]. The Hisayama Study, using three study cohorts
from 1961, 1974, and 1988, reported that the age-
standardized incidence of CAD had been increasing in

































































































































Fig. 7 Trend of percentage of individuals with BMI ≥25 kg/m2 by age [18]. BMI, body mass index
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The mechanisms of increasing trend of AMI in Japan
include westernization of lifestyle, increased prevalence of
DM, increased levels of TC in serum, increased BMI in
men, and a high prevalence of hypertension and smoking.
Although the incidence rate of AMI in Japan remains low,
aggressive reduction of such cardiovascular risks must be
emphasized to prevent the development of AMI.
Elderly individuals and CVD
In general, atherosclerosis takes a long time to develop.
Most elderly individuals have some degree of atheroscle-
rosis, and >80% of all cardiovascular deaths occur in
individuals aged ≥65 years [44]. In many countries, the
mortality rate from CAD and stroke has been decreasing
steadily since the late 1960s. However, the reduction in
mortality has been particularly observed in middle-aged men;
the elderly population has not shown a substantial decrease in
cardiovascular mortality [44]. Statistical data from Japan have
also shown a decreasing trend in the crude cardiovascular
mortality rate across all age groups since 1990. However,
since 1950, there has been a dramatic increase in the mortality
from heart diseases among individuals aged ≥75 years and a
moderate increase in the mortality from heart disease was
observed in men aged 65–74 years (Fig. 10) [7]. The Tokyo
Fire Department of the Fire and Disaster Management
Agency in Japan sent 700808 ambulance services in 2010.
It reported that the number of individuals aged ≥65 years who
utilized the service for a sudden illness was 277077 (39.5%),
which was an increase in the figure from 2003 (Fig. 11); one
of the major reasons for this trend was the rapid increase in
the elderly population in Tokyo [45].
Many of the elderly individuals are at a much higher
cardiovascular risk than any other age group. However, the
magnitude of risks and benefits of risk mitigation between
the elderly and the younger or middle-aged population
might be different.
Hypercholesterolemia or a high level of LDL-C is a
major risk factor for developing CAD in the general
population. However, in observational studies, this associ-
ation in the older population is controversial [46]. One of
reasons for the discrepancy in this association between
middle-aged and older populations is that comorbidity is
frequently observed in the elderly and this may cause
acquired low levels of cholesterol. There were several
reports showing that lipid-lowering treatment using 3-
hydroxy-3-methyl-glutaryl-CoA reductase inhibitors signif-
icantly reduced coronary events in the older age group
similar to those in the middle-aged population in primary
and secondary prevention trials [46, 47].
Hypertension is a definite risk factor for the development
of CVD in the elderly population [48]. Many large
prospective trials also documented the clear benefit of
antihypertensive treatment in elderly patients with hyper-
tension. A meta-analysis involving 5 trials in hypertensive
patients aged ≥60 years showed that antihypertensive
agents resulted in a 19% reduction in CAD, which was
similar to that seen in younger individuals [49]. Further-
more, Mulrow et al. reported that the short-term benefits in
morbidity and mortality of treatment were greater in elderly
than in younger patients [50]. The Hypertension in the Very
Elderly Trial reported that antihypertensive treatment with
indapamide in patients aged ≥80 years was beneficial with
significant reduction in death rate from cardiovascular
causes or the development of HF [51].
Smoking is an established risk for the development of
new CVDs in the elderly, although its relative contribution
decreases with increasing age [52]. Furthermore, older
people who cease smoking after 70 years of age showed a
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Fig. 9 Trend of mortality rate by various heart diseases [7]. AMI, acute myocardial infarction; CAD, coronary artery disease
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significant reduction in the development of new myocardial
infarction or death [53].
DM or poor glycemic control are associated with an
increased incidence of cardiovascular events in elderly men
and women [54, 55]. However, the relative effects of DM
on CVDs are weaker among older patients compared with
younger patients [56].
Atherosclerosis is not the only abnormality associated
with the development of symptomatic CVD. Triggering
factors (e.g., increased coagulation activity, increased
activity of sympathetic nervous system, vasoactive hor-
mone, smoking) which might be more frequently observed
in elderly individuals also play an important role (especially
in artery-occlusive diseases). The most effective strategies
preventing the development of HF and the progression of
CVD are reduction of modifiable cardiovascular risks and
elimination of triggering factors that causes sudden arterial
occlusion or decompensation of HF. However, under-
treatment or insufficient control of cardiovascular risks
may be more prominent in elderly patients. National Health
and Nutrition Examination Survey III showed that only 23–
46% of patients with hypertension aged >70 years showed
adequate control of BP [57]. Our previous cohort study of
HF patients: (the CHART-1 Study) revealed that the
penetration rate of standard HF treatment such as renin-
angiotensin system (RAS) inhibitors and β-blockers was
significantly lower in elderly patients, which was validated
by multivariate logistic regression analyses [58].
Some elderly individuals have comorbidities that represent
a significant association with CVD. Chronic kidney disease
(CKD) is an extensive public-health problem and is observed
in 9–13% of the general population [59]. The prevalence of
CKD increases with age and many reports have clarified that
CKD is an important risk factor for the development and
worsening of CVD [59, 60]. Chronic obstructive pulmonary
disease (COPD) is the fourth most frequent cause of death;
approximately 400000 deaths occur each year from COPD in
developed countries [61]. COPD is one of the persistent
systemic inflammatory disorders (like CVD or HF) and is
strongly associated with the elderly population (probably as a
result of the long-term exposure to risk factors such as
cigarette smoking) [61]. Recent reports showed that COPD
was a significant risk factor for developing CVD and
cardiovascular death. Mazza et al. reported that COPD was
an independent risk factor for cardiovascular mortality in
hypertensive individuals [62]. Kjøller et al. also revealed that
COPD was a predictor of mortality in patients with AMI
when evaluating 6669 subjects included in the Trandolapril
Cardiac Evaluation Study [63]. Further research should be
emphasized to evaluate such extra cardiac risks for CVD and
to recognize novel prognostic risks (particularly in the
elderly population).
The pathophysiology of CVD or HF is more complicated
and heterogeneous in elderly patients. Furthermore, such
patients usually have non-cardiovascular comorbidities
(including chronic diseases) which sometimes complicate
appropriate diagnosis and treatment. Conventional diagnos-
























































Fig. 10 Trend of number of individuals who died from heart diseases by age [7]
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younger or middle-aged patients. Importantly, there is no
sufficient clinical evidence for treating elderly patients with
CVD or HF. Thus a personalized approach is necessary in
the prevention and management of HF in elderly patients.
CHART-2 study
The prevalence and crude mortality rate of CVD has been
relatively lower in Japan compared with that in Western
countries. However, it has been rapidly increasing due to
the westernization of lifestyle, increased risk of atheroscle-
rosis, and a rapidly aging population [7, 9]. Our previous
cohort study of HF patients, the CHART-1 Study, revealed
that the most prevalent etiology of HF in Japan was non-
ischemic cardiomyopathy (28.6%) and only 25.4% of HF
was attributed to CAD (which is the leading cause of HF in
most Western countries) [8]. We started a multicenter
prospective cohort study, the CHART-2 Study, in October
2006 to evaluate the clinical characteristics and prognosis
of Japanese patients at high risk for disease progression of
CVD or those with overt HF [14]. The study was conducted
in collaboration with 24 hospitals in the Tohoku district;
this is in the north-east of Japan and has a population of 9.8
million. Stable patients aged ≥20 years were consecutively
enrolled in the study who were suffering from CAD or were
in stage B, C, or D as defined by the Guidelines for the
Diagnosis and Management of HF in Adults of the ACC
Foundation/AHA [10]. The entry period of the CHART-2
Study was closed in March 2010 (N=10219), which made
this study the largest-scale cohort of CVD in Japan [64].
Characteristics of Japanese patients with CVD but without
HF
The CHART-2 cohort involved 5484 patients (53.7%) with
CVD but without HF. These patients were characterized by
younger age (67.6±12.2 years), higher number of males
(71.0%), less severe symptom, and higher values of
ejection fraction (EF, 65.5±11.7%) compared with those
in stage C or D. However, the prevalence of cardiovascular
risks such as hypertension (75.4%), DM (21.9%), and
dyslipidemia (72.7%) was similarly high. The prevalence of
current smokers was also high, 23.3% (men) and 5.9%
(women). CAD was the most prevalent etiology accounting
for 58.2% of patients in stage B. Furthermore, B-type
natriuretic peptide (BNP) level was mildly elevated in
patients in this category (97.6±188.1 pg/mL) and 32.4% of
patients had CKD. Usage rates of RAS inhibitors and β-
blockers were 57.9% and 33.0%, respectively.
HF stage progression and exacerbation in prognostic risks
Background characteristics of CHART-2 patients showed a
graded appearance of HF stage on CVD severity [14]. For
example, as the HF stage progressed from stage B to stage
D, left ventricular end-diastolic dimension increased, left
ventricular EF decreased, and BNP level increased signif-
icantly (Fig. 12). Furthermore, recently underscored
kidney-related risks were also exacerbated with progression
of HF stage; the estimated glomerular filtration rate (GFR)
decreased, hemoglobin level decreased, and the urine
































































LVDd LVEF BNPFig. 12 LV dimension, EF, and
BNP of CHART-1 and CHART-2
patients [14]. BNP, B-type na-
triuretic peptide; CAD, coronary
artery disease; Dd, diastolic di-
mension; EF, ejection fraction;
LV, left ventricular
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The accumulation of prognostic risks with HF stage
included significant increases in age, heart rate, cardiotho-
racic ratio, and uric acid level, as well as significant
decreases in BP, BMI, and LDL-C level [14].
Characteristics of Japanese patients with HF
The stage-C and -D groups, which were considered to be
patients with overt HF, accounted for 45.4% and 0.9% of
the total number of enrolled patients, respectively. The most
prevalent etiology of HF in the CHART-2 Study was CAD
(47.1%) and it was almost comparable with the prevalence
of HF etiology in Western observational cohort studies of
HF (Fig. 14) [8, 65–69]. CAD as an etiology of HF has
dramatically increased compared with that in the CHART-1
Study, which was undertaken approximately 6 years before
the CHART-2 Study. The prevalence of hypertension and
DM as comorbidities in CHART-2 patients was similar to
that in Western studies (Fig. 15). Meanwhile, left ventric-
ular EF at study entry was relatively higher and the
prevalence of patients with preserved EF was considerably
higher when HF patients in the CHART-2 Study were
compared with those in studies of Western countries
(Fig. 16). HF patients with preserved EF in the CHART-1
and −2 Studies were observed more frequently among
elderly patients, just as in previous studies in Western
countries [14, 58, 68, 69]. Comparisons of the usage rates
of medical treatments for HF patients are shown in Fig. 17.
HF patients in the CHART-2 Study were characterized by
lesser use of loop diuretics and a higher use of angiotensin-II
receptor blockers, but usage ofβ-blockers and RAS inhibitors







































































GFR Hemoglobin UACRFig. 13 GFR, hemoglobin lev-
el, and urine albumin creatinine
ratio of CHART-1 and CHART-2
patients [14]. CAD, coronary
artery disease; GFR, glomerular



































Fig. 14 Etiology of HF in
Western patients and CHART
patients [14]. Framingham, ref-
erence [65]; ADHERE, refer-
ence [66]; EHFS II, reference
[67]; Owan, reference [68];
Bhatia, reference [69]; CHART-
1, reference [8]; CHART-2,
reference [14]
434 EPMA Journal (2011) 2:425–438
Primary results of the CHART-2 Study suggest that there
has been a clear trend of increasing westernized etiology
and risks among HF patients in Japan. Findings from the
CHART-1 Study showed that HF patients with CAD had a
poorer prognosis compared to those with non-ischemic
cardiomyopathy [70]. Furthermore, it was predicted that the
number of elderly HF patients will increase considerably in
the near future and these patients showed a significantly
increased rate of cardiovascular events and mortality [9].
The CHART-2 Study revealed that patients in stage B or
with CAD had a higher prevalence of cardiovascular risks,
elevated BNP level and possible under-treatment of risk
control, even though these patients did not show any overt HF
symptoms. These findings clearly suggested that patients in
stage B or with CAD were significantly vulnerable to
developing HF in the future. We have to make an accurate
risk stratification of all patients in stage B or with CAD and
urge aggressive treatment in such patients (as well as in
patients in stage C or D) to improve the quality of life (QOL)
and prognosis of all patients with CVD.
Predictive, preventive, and personalized medicine in HF
patients in Japan
Predictive, preventive, and personalized medicine is a new
approach in managing chronic diseases. HF is one of the
diseases that need this new philosophy to reduce prevalence
and to improve long-term outcomes and QOL. Given the
future increase in the number of HF patients in Japan,
management must implement 5 main strategies at each
stage of development and progression of HF. Firstly, there
must be an accurate prediction of individuals at a higher
risk of disease progression or development of HF using
biomarkers and prognostic risks (e.g., BNP, EF, GFR, and
other authorized risk factors). Secondly, effective preven-
tion of disease progression through appropriate treatments
based on evidence-based guidelines is necessary. Thirdly,
optimally personalized treatments (especially in elderly
















































Mean Ejection Fraction HFpEF
Fig. 16 EF and prevalence of HF patients with preserved EF in
Western patients and CHART patients [14]. Framingham, reference
[65]; ADHERE, reference [66]; Owan, reference [68]; Bhatia,
reference [69]; CHART-1, reference [8]; CHART-2, reference [14];




























Fig. 15 Prevalence of hypertension and DM in Western patients and
CHART patients [14]. Framingham, reference [65]; ADHERE,
reference [66]; Owan, reference [68]; Bhatia, reference [69];
























Fig. 17 Medication in patients with HF in Western patients and
CHART patients [14]. ADHERE, reference [66]; EHFS II, reference
[67]; CHART-1, reference [8]; CHART-2, reference [14]
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required. Fourthly, we need a lifelong approach for
preventing the development of HF and caring for HF
patients. CVD or HF usually needs a long time to develop;
but, atherosclerosis starts to develop early in youth or even
in childhood. Finally, the translation of genomic medicine
(including gene expression, proteomics, metabolomics,
molecular imaging) into a prospective personalized health
plan is one of the promising strategies in the near future.
Subsets of such approaches are available in cardiology, but
these issues are beyond the scope of this contribution.
Conclusions and outlook
In Japan, a rapidly aging population and westernization of
cardiovascular risks have led to an increase in the number of
patients with CVD and HF. These trends may contribute in
progression of CVD and further deteriorate the prognosis of
such patients.
Given the progressive nature of the disease, an appro-
priate prospective approach is needed in the management of
HF. Patients at a higher risk of developing HF must be
predicted using biomarkers and other prognostic risk
factors. Effective prevention of HF in Japan includes the
strict control of westernized risks based on clinical guide-
lines to reduce the development of CAD, risk stratification
of patients in stage B or those with CAD, and delaying the
stage progression of CVD with personalized medical or
surgical treatment. The number of elderly patients with
CVD or HF has been increasing. Hence, we must urge
lifelong risk management in the general population as well.
In addition, we need further studies to clarify the
pathophysiology of HF with preserved EF and to determine
novel risks that exacerbate the severity of CVD and HF.
Predictive, preventive, and personalized medicine must be
appropriately applied in patients with CVD or HF as well as
in those at future risk of such diseases.
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